Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro

Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In... The initiation of cell-mediated immunity to Epstein-Barr virus (EBV) has been analyzed with cells from EBV-seronegative blood donors in culture. The addition of dendritic cells (DCs) is essential to prime naive T cells that recognize EBV-latent antigens in enzyme-linked immunospot assays for interferon γ secretion and eradicate transformed B cells in regression assays. In contrast, DCs are not required to control the outgrowth of EBV-transformed B lymphocytes from seropositive donors. Enriched CD4 + and CD8 + T cells mediate regression of EBV-transformed cells in seronegative and seropositive donors, but the kinetics of T-dependent regression occurs with much greater speed with seropositives. EBV infection of DCs cannot be detected by reverse transcription–polymerase chain reaction with primers specific for mRNA for the EBNA1 U and K exons. Instead, DCs capture B cell debris and generate T cells specific for EBV latency antigens. We suggest that the cross-presentation of EBV-latent antigens from infected B cells by DCs is required for the initiation of EBV-specific immune control in vivo and that future EBV vaccine strategies should target viral antigens to DCs. herpesvirus regression assay cross-priming T cell B cell Footnotes The online version of this article includes supplemental material. Abbreviations used in this paper: CSA, cyclosporin A; EBV, Epstein-Barr virus; HD, Hodgkin's disease; IM, infectious mononucleosis; LCL, lymphoblastoid cell line; PTLD, posttransplant lymphoproliferative disease; vv, vaccinia viruses. Submitted: 21 April 2003 Accepted: 10 October 2003 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Journal of Experimental Medicine Rockefeller University Press

Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro

Loading next page...
 
/lp/rockefeller-university-press/dendritic-cells-initiate-immune-control-of-epstein-barr-virus-74xbtoL1VT

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Rockefeller University Press
Copyright
© 2003 Rockefeller University Press
ISSN
0022-1007
eISSN
1540-9538
DOI
10.1084/jem.20030646
pmid
14657218
Publisher site
See Article on Publisher Site

Abstract

The initiation of cell-mediated immunity to Epstein-Barr virus (EBV) has been analyzed with cells from EBV-seronegative blood donors in culture. The addition of dendritic cells (DCs) is essential to prime naive T cells that recognize EBV-latent antigens in enzyme-linked immunospot assays for interferon γ secretion and eradicate transformed B cells in regression assays. In contrast, DCs are not required to control the outgrowth of EBV-transformed B lymphocytes from seropositive donors. Enriched CD4 + and CD8 + T cells mediate regression of EBV-transformed cells in seronegative and seropositive donors, but the kinetics of T-dependent regression occurs with much greater speed with seropositives. EBV infection of DCs cannot be detected by reverse transcription–polymerase chain reaction with primers specific for mRNA for the EBNA1 U and K exons. Instead, DCs capture B cell debris and generate T cells specific for EBV latency antigens. We suggest that the cross-presentation of EBV-latent antigens from infected B cells by DCs is required for the initiation of EBV-specific immune control in vivo and that future EBV vaccine strategies should target viral antigens to DCs. herpesvirus regression assay cross-priming T cell B cell Footnotes The online version of this article includes supplemental material. Abbreviations used in this paper: CSA, cyclosporin A; EBV, Epstein-Barr virus; HD, Hodgkin's disease; IM, infectious mononucleosis; LCL, lymphoblastoid cell line; PTLD, posttransplant lymphoproliferative disease; vv, vaccinia viruses. Submitted: 21 April 2003 Accepted: 10 October 2003

Journal

The Journal of Experimental MedicineRockefeller University Press

Published: Dec 1, 2003

There are no references for this article.